Silence Therapeutics plc 8-K

What Happened
Silence Therapeutics plc filed an 8-K on June 11, 2026, furnishing a press release that highlights follow-up and quality-of-life (QoL) data from the Phase 1 SANRECO study of divesiran. The data, presented at the European Hematology Association (EHA) 2026 Annual Congress, relate to divesiran — a first-in-class siRNA therapy that targets TMPRSS6 — tested in 21 phlebotomy-dependent patients with polycythemia vera (PV). The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Study: Phase 1 SANRECO; therapy: divesiran (siRNA targeting TMPRSS6).
• Patient population: 21 phlebotomy-dependent patients with polycythemia vera.
• Event/date: Data presented at EHA 2026; 8-K and press release filed/furnished on June 11, 2026 (Exhibit 99.1).
• Administrative: 8-K signed by Iain Ross, Interim Principal Executive Officer and Chairman.

Why It Matters
This filing is a clinical update rather than a financial report. Follow-up and QoL data from early-stage trials can be material to investors because they inform the therapy’s safety, tolerability and patient benefit profile, which are factors in development decisions, partnering interest and future regulatory planning. The company did not report financial results or changes in leadership in this filing.